Wells Fargo Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $27
Reported Saturday, Travere Therapeutics Revealed Data Reinforcing Clinical Benefit Of FILSPARI In IgAN And Late-Breaking Presentation In FSGS At ASN Kidney Week 2024
Express News | Travere Therapeutics Inc: Interim Data From Spartacus Study Demonstrated That Filspari, When Added to Stable Sglt2I, Was Generally Well Tolerated
Earnings Preview: TVTX to Report Financial Results Pre-market on October 31
$Travere Therapeutic(TVTX.US)$ is scheduled to release its financial results pre-market on October 31 ET. Earnings PreviewAnalysts estimate $Travere Therapeutic(TVTX.US)$ to post revenue of USD61.15
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Travere Therapeutics to Report Third Quarter 2024 Financial Results
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
12 Health Care Stocks Moving In Thursday's After-Market Session
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday
Travere Therapeutics Receives Swiss Regulator's Temporary Marketing Approval for Kidney Disease Treatment
Express News | CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy
Scotiabank Initiates Travere Therapeutics at Sector Outperform With $23 Price Target
Travere Therapeutics To Present 11 Abstracts, Including One Late-breaking Abstract At Upcoming American Society Of Nephrology Kidney Week 2024 In San Diego, October 23-27
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $41
Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Travere Therapeutics Shares Are Trading Higher After Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $17 to $25.
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $41